SCHEMBL30055652

SCHEMBL30055652

N#CC(=C1CCN(C(=O)N2CCc3nocc3C2)CC1)c1ccc(F)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.44
ELANE P08246 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
GRM5 P41594 2/20 0.34
HSD11B1 P28845 1/20 0.32
KCNQ3 O43525 2/20 0.31
KCNQ2 O43526 2/20 0.31
GABRG2 P18507 2/20 0.31
GABRB3 P28472 2/20 0.31
GABRA5 P31644 2/20 0.31
KCNH2 Q12809 2/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
HSD17B10 Q99714 1/20 0.31
PROKR1 Q8TCW9 3/20 0.30
PGR P06401 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27166125 1.00 NAMPT (0.44) NAMPTELANEMEN1KMT2AGRM5
SCHEMBL27166039 0.89 NAMPT (0.51) NAMPTELANEGRM5GABRG2GABRB3
SCHEMBL27166078 0.87 PROKR1 (0.41) NAMPTELANEMEN1KMT2APROKR1
SCHEMBL27166194 0.87 NAMPT (0.44) NAMPTELANEGRM5GABRG2GABRB3
SCHEMBL30057798 0.85 GRM5 (0.38) NAMPTELANEMEN1KMT2AGRM5
SCHEMBL27166081 0.85 GRM5 (0.38) NAMPTELANEMEN1KMT2AGRM5
SCHEMBL27166200 0.84 NAMPT (0.40) NAMPTELANEMEN1KMT2AGRM5
SCHEMBL29205150 0.83 NAMPT (0.44) NAMPTELANEMEN1KMT2AGABRG2
SCHEMBL29205123 0.82 NAMPT (0.38) NAMPTELANEPROKR1
SCHEMBL27166178 0.82 PROKR1 (0.46) NAMPTELANEHSD11B1PROKR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637471-B2 Heterocyclic compounds, compositions, methods of preparation and uses thereof ORGANON R&D FINLAND LTD. (FI) 2026-05-26 US disclosed
EP-4334289-B1 NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF Organon R&D Finland Oy (FI) 2025-06-25 EP disclosed
US-20240254131-A1 NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF ORGANON R&D FINLAND LTD. (FI) 2024-08-01 US disclosed
CN-117794899-A Novel heterocyclic compounds, compositions, methods of preparation and uses thereof 欧加农研发芬兰有限公司 2024-03-29 CN disclosed
EP-4334289-A1 NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF Organon R&D Finland Ltd (FI) 2024-03-13 EP disclosed
WO-2022234193-A1 NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF FORENDO PHARMA LTD (FI) 2022-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254131-A1 NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF AKR1C3, AKR1C4, AKR1C1 NAMPT 602/4885ELANE 2466/4885MEN1 3066/4885
US-12637471-B2 Heterocyclic compounds, compositions, methods of preparation and uses thereof AKR1C3, AKR1C4, AKR1C2 NAMPT 2385/4885ELANE 2531/4885MEN1 3860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.